Companies › Wuhan YZY Biopharma
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| M701 anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody | EPCAM, CD3E | Phase 3 | Malignant Ascites; Malignant Pleural Effusions | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06432296 | M701 | Phase 3 | Malignant Ascites | Oncology | Dec 2026 |
| NCT05543330 | M701 | Phase 1 | Malignant Pleural Effusions | Oncology | Dec 2026 |
Johnson & Johnson (Janssen) BioAtla Regeneron Pharmaceuticals Amgen Roche AstraZeneca AcadeMab Biomedical Mirador Therapeutics Tiziana Life Sciences Sanofi
LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.